Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers
NCT ID: NCT02801305
Last Updated: 2017-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2016-06-30
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Ozone Therapy for the Treatment of Digital Ulcer in Patients With SSc
NCT04826419
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
NCT05168215
Platelet Gel in Systemic Sclerosis
NCT00463125
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers
NCT03406988
Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis
NCT00624273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Systemic sclerosis, also named scleroderma (SSc), is an autoimmune connective tissue disease associated with small vessels vasculopathy and collagen deposition in skin and other internal organs \[1, 2\]. About 30-60 % of patients with limited and diffused type of scleroderma developed by digital ulcers (DUs) in course of their disease \[3\]. Depending on the sites of the ulcers, their pathophysiology is differed. The ones on distal parts of the digits are related to ischemic changes based on Raynaud phenomenon, intimal fibroproliferation, and thrombosis; while, the ones on bony prominences are mostly due to microtrauma and following poor vascularization for its healing \[4\].
These ulcers can affect the quality of life of the patients mostly due to the pain and difficulty in their healing \[3\]. Accordingly, several therapies have been introduced for improving its healing process. Among them, nitroglycerin ointment was assessed to be an effective topical agent on Raynaud phenomenon; however, there can be found only one study assessing its effect on SSc digital ulcer, which was shown to be non significant \[5-7\].
Calcium channel blockers (CCB) such as diltiazem are also being used for Raynaud phenomenon in scleroderma patients. Yet, some of their potential side effects such as peripheral edema, hypotension, and headache limit the up titration of these classes of drugs \[8\]. Moreover, their therapeutic effects on SSc digital ulcers are still being questionable. Only, one clinical trial assessed the effect of nifedipine on ulcer healing, which resulted in non-significant difference compared with placebo\[7\].
In addition to systemic form of CCBs, topical form of them such as diltiazem gel is also being available. Previous studies introduced this form of diltiazem as a vasodilator, mostly, for treatment of chronic anal fissure \[9\]. Comparing its effects with topical nitrate for chronic anal fissures showed some controversies. Some studies resulted in no significant difference between them; yet, the study by Ala et al, demonstrated that diltiazem gel has superiority to nitroglycerin ointment \[10, 11\]. Another survey, in spite of finding non- significant difference between these two agents in treatment of anal fissure, gave priority to diltiazem gel because of headache induced by nitroglycerin ointment \[12\].
As it can be inferred from previous studies, most of the medications used for scleroderma DU healing are drugs applied for Raynaud phenomenon. In spite of the determined therapeutic effects of such drugs on this phenomenon, their efficacy on healing of DUs is still being obscured. Furthermore, because of the complications of systemic therapies and limitation in their dose up titrating, topical agents are being preferred. However, there has not still found an effective topical therapy for DU of scleroderma patients.
The effect of topical diltiazem as a vasodilator agent in treatment of anal fissure brings to mind this idea that it may be also effective in healing of scleroderma DUs. In addition, comparing the effect of diltiazem gel and topical nitrate in anal fissures, generally, suggest the preference of the former. However, there can not be found any survey comparing the effects of these two topical vasodilators in treatment of DU. Thus, in this study, we aim to assess the effect of topical diltiazem on SSc digital ulcers and compare it by topical nitroglycerin.
Material and Method:
A single blind case control study will be done on 90 scleroderma patients registered in Tertiary Centers of rheumatology diseases of Shiraz University of Medical Sciences, Shiraz, Iran. (The sample size was estimated using the formula of n = (Zα/2+Zβ)2 \* (p1(1-p1)+p2(1-p2)) / (p1-p2)2 \[ Zα/2 is the critical value of the Normal distribution at α/2 (for a confidence level of 95%, α is 0.05 and the critical value is 1.96), Zβ is the critical value of the Normal distribution at β (for a power of 80%, β is 0.2 and the critical value is 0.84) and p1 and p2 are the expected sample proportions of the two groups\]).
Inclusion Criteria:
The patients' scleroderma was diagnosed based on criteria of LeRoy\[13\]. The ones with ages between 20-70 years old will be entered into the study. They, all, should have at least one active digital ulcer.
Exclusion Criteria:
The cases with comorbid diseases such as diabetes, thyroid disease and cardiovascular diseases will be excluded from the survey. Moreover, the patients who are smoker, opium addict or alcohol abuser will also drop out of the study. In addition, the ones who received inhaled or oral prostanoid in last 3 months, phosphodiesterase inhibitors except for intermittent treatment of erectile dysfunction in last 1 month and the ones received antibiotics 2 weeks prior to the study will, also, be excluded. The baseline hepatic function test will be assessed and the cases with moderate to severe hepatic impairment or increase in aminotransferase levels more than 3 will also be excluded from the survey.
The study design:
The patients will be divided into 3 groups; one control group consisting of 30 cases, and two experimental groups with 30 patients in each of them. The control one (C) receiving Vaseline ointment as placebo, the experimental group 1 (E1) which will receive diltiazem gel (2%) applied on DUs two times daily and experimental group 2 (E2) treating by nitroglycerin ointment (2%) applied two times daily for 8 weeks.
The number of the DUs and the mean diameter of all DUs will be measured in 3 groups at the beginning and at the end of the study. Moreover, the site of the ulcers (fingertip, proximal interphalangeal joint (PIP), distal interphalangeal joint (DIP), metacarpophalangeal joint (MCP)) will be also taken into account and be submitted for each patient.
The number of new DUs developing during the study and the difference between mean diameters of them will be compared between 3 groups. In addition, the difference in mean of DUs in different sites will also be compared to see which site has more responsiveness to topical therapeutic agents used in this survey.
Ethical Issues:
Informed consent to the entire protocol as well as forms compatible with Helsinki Declaration was obtained from each patient. Ultimately, the ones who agreed to enroll will be recruited for the study.
Statistical Analysis:
Data will be entered into SPSS 19. For comparing the number and mean difference of digital ulcers' diameters between 3 groups and between different sites of the ulcer, one-way ANOVA will be applied. In addition, Bonferroni test as the post hoc of ANOVA will be applied for pairwise comparison of the groups. The significant p-value in all studies will be considered \<0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaseline
About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
Vaseline
This is used as the topical placebo agent.
Diltiazem Gel 2%
About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
Diltiazem Gel 2%
This a topical agent which will be applied on digital ulcers by scleroderma patients.
Nitroglycerin Ointment 2%
About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
Nitroglycerin Ointment 2%
This a topical agent which will be applied on digital ulcers by scleroderma patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diltiazem Gel 2%
This a topical agent which will be applied on digital ulcers by scleroderma patients.
Nitroglycerin Ointment 2%
This a topical agent which will be applied on digital ulcers by scleroderma patients.
Vaseline
This is used as the topical placebo agent.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having ages between 20-70 years old
* Having at least one active digital ulcer
Exclusion Criteria
* Being smoker, opium addict or alcohol abuser
* Ones received inhaled or oral prostanoid in last 3 months, phosphodiesterase inhibitors except for intermittent treatment of erectile dysfunction in last 1 month and the ones received antibiotics 2 weeks prior to the study
* The ones with moderate to severe hepatic impairment or increase in aminotransferase levels more than 3
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Mohammad Ali Nazarinia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Ali Nazarinia
Associate Professor of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammad Ali Nazarinia, M.D.
Role: STUDY_DIRECTOR
Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheumatology Reseach Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509-37. doi: 10.1146/annurev-pathol-011110-130312.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985-93. doi: 10.1002/art.20676.
Ngcozana T, Ong V, Denton CP. Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists. BMJ Case Rep. 2014 Mar 28;2014:bcr2013203174. doi: 10.1136/bcr-2013-203174.
Herrick AL, Gush RJ, Tully M, Jayson MI. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma. Ann Rheum Dis. 1994 Mar;53(3):212. doi: 10.1136/ard.53.3.212-a. No abstract available.
Abraham S, Steen V. Optimal management of digital ulcers in systemic sclerosis. Ther Clin Risk Manag. 2015 Jun 15;11:939-47. doi: 10.2147/TCRM.S82561. eCollection 2015.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001 Jul;28(7):1573-6.
Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford). 2002 Mar;41(3):324-8. doi: 10.1093/rheumatology/41.3.324.
Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013 Sep;65(9):1460-71. doi: 10.1002/acr.22018.
Tsunoda A, Kashiwagura Y, Hirose K, Sasaki T, Kano N. Quality of life in patients with chronic anal fissure after topical treatment with diltiazem. World J Gastrointest Surg. 2012 Nov 27;4(11):251-5. doi: 10.4240/wjgs.v4.i11.251.
Bulus H, Varol N, Tas A, Coskun A. Comparison of topical isosorbide mononitrate, topical diltiazem, and their combination in the treatment of chronic anal fissure. Asian J Surg. 2013 Oct;36(4):165-9. doi: 10.1016/j.asjsur.2013.01.010. Epub 2013 Mar 6.
Ala S, Saeedi M, Hadianamrei R, Ghorbanian A. Topical diltiazem vs. topical glyceril trinitrate in the treatment of chronic anal fissure: a prospective, randomized, double-blind trial. Acta Gastroenterol Belg. 2012 Dec;75(4):438-42.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
95010111653
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.